GNCA News Alert Genocea Biosciences Inc. (GNCA) 7.42 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genocea Biosciences Inc. (GNCA) 7.42 $GNCA

Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.03), PFNX: 7.33 (-0.05), INO: 9.11 (-0.09), CMRX: 36.80 (+0.70), RPTP: 9.34 (+0.56), IBIO: 0.68 (-0.04), ANAC: 30.58 (+0.16), PFE: 31.42 (-0.03), GNCA: 7.42 (-0.11), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), NVS: 93.91 (+0.66)

Genocea Appoints Eric S. Hoffman as Chief Business Officer
Business Wire - Mon Dec 15, 9:55AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Eric S. Hoffman has joined the company as chief business officer.
GNCA: 7.42 (-0.11)

Epizyme selects Kenneth Bate to board
M2 - Mon Dec 15, 5:49AM CST
Biopharmaceutical company Epizyme (NasdaqGS:EPZM) revealed on Friday that Kenneth Bate has been named to its board of directors.
EPZM: 17.71 (+0.01), GNCA: 7.42 (-0.11)

Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST

AGEN: 3.85 (unch), VICL: 1.03 (+0.02), MRK: 57.46 (+0.25), GNCA: 7.42 (-0.11)

Genocea to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 8:06AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present at the following upcoming conferences:
GNCA: 7.42 (-0.11)

Genocea secures new capital
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:40AM CST

HTGC: 15.13 (+0.39), GNCA: 7.42 (-0.11)

Genocea Secures Debt Facility from Hercules Technology Growth Capital of up to $27 Million
Business Wire - Fri Nov 21, 7:30AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $27.0 million.
HTGC: 15.13 (+0.39), GNCA: 7.42 (-0.11)

Genocea Named in Top Places to Work List by The Boston Globe
Business Wire - Thu Nov 13, 10:52AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston's Top Places to Work by The Boston Globe.
GNCA: 7.42 (-0.11)

Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference
Business Wire - Wed Nov 12, 7:02AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 19, 2014 at 10:20 a.m. EST in New York, NY.
GNCA: 7.42 (-0.11)

Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 34.96 (+0.78), CMRX: 36.80 (+0.70), CVM: 0.62 (+0.03), ADMP: 5.17 (+0.06), GNCA: 7.42 (-0.11)

Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:49AM CST

GNCA: 7.42 (-0.11)

Genocea Biosciences misses by $0.02
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:26AM CST

GNCA: 7.42 (-0.11)

Genocea Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the third quarter ended September 30, 2014.
GNCA: 7.42 (-0.11)

Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes
Business Wire - Wed Nov 05, 11:01AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of antigens that may be a biomarker of disease. The findings, generated using Genocea's proprietary ATLAS(TM) antigen discovery platform, revealed that malaria leaves a lasting imprint on the immune system. Genocea researchers found evidence that this T cell immunological memory can be detected many years after the previous clinical episode of malaria. The study was presented at the 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene in New Orleans, LA.
GNCA: 7.42 (-0.11)

Genocea to Announce Third Quarter 2014 Financial Results on November 6, 2014
Business Wire - Thu Oct 30, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on November 6, 2014 at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 7.42 (-0.11)

Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 42.29 (+1.79), NVAX: 5.81 (+0.18), AMPE: 3.43 (+0.17), GNCA: 7.42 (-0.11)

Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek
Business Wire - Wed Oct 08, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the presentation of final data from the Phase 1/2a study of GEN-003, the company's immunotherapy candidate for treatment of genital herpes. The oral presentation, titled "Therapeutic HSV-2 Vaccine (GEN-003) Results in Durable Reduction in Genital Lesions at 1 Year ", will be given on Saturday, Oct. 11 at IDWeek 2014(TM) in Philadelphia.
GNCA: 7.42 (-0.11)

Genocea wins USD1.2m grant for malaria vaccine discovery
M2 - Wed Sep 24, 6:11AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Tuesday that it has received a USD1.2m grant for the identification of protective T cell antigens for malaria vaccines.
GNCA: 7.42 (-0.11)

Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery
Business Wire - Tue Sep 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.
GNCA: 7.42 (-0.11)

Genocea to Present at the 21st Annual NewsMakers in the Biotech Industry Conference
Business Wire - Fri Sep 19, 8:00AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the BioCentury 21st Annual NewsMakers in the Biotech Industry Conference. The presentation is scheduled for Friday, September 26, 2014 at 10:30 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York, NY.
GNCA: 7.42 (-0.11)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading